Cheetah Medical

Cheetah Medical — the system developer of noninvasive monitoring of infusions under the name Starling SV. Touch laying of the device is imposed on a thorax, allowing to estimate function of heart and to define the amount of liquid necessary for the patient for maintenance of optimal perfusion of bodies and fabrics. The technology is intended for operating rooms, intensive care units and emergency aid. The company was founded in 2000 in Boston.

History

2019: Baxter International purchased Cheetah Medical

In the middle of September, 2019 Baxter International stated that it is ready to purchase Cheetah Medical company for the amount to $230 million - $190 million in the form of a primary deposit and also in addition $40 million which should be paid on reaching certain clinical and commercial results.

The CEO of Baxter José Almeida, making in January the income statement of the company in the fourth quarter 2018, explained that Baxter looks for possible takeover targets which will allow to provide long-term growth in the areas adjoining the current activities of the company. Cheetah Medical meets these requirements and is capable to add possibilities of Baxter which takes the leading positions in the field of production of the infusional systems and intravenous solutions.

Baxter International stated that it is ready to purchase Cheetah Medical company

Baxter intends to include Cheetah technology in the new integrated platform for specialized monitoring of patients. As reported in the company, the Starling SV technology will allow to control successfully a status of patients with sepsis, intense injury of kidneys and other critical conditions. The research conducted in 2017 by the University of Kansas Medical Center showed that effective control of infusion reduces stay in intensive care unit on average by 2.89 days and reduces risk of artificial ventilation of lungs and the beginning of sharp dialysis.^[1]

Notes